Monday, July 18, 2016
The Alliance for Multispecialty Research (AMR), which includes some of the most experienced independent clinical research centers in the U.S., has established a new business model that fully integrates its 17-member network and better positions the organization to collaborate with sponsors and CROs in preferred provider site networks and strategic partnerships.
Major trends in drug development will reshape the global investigative site landscape. Trends to look out for include patient centricity and big data to CROs assuming responsibility for site effectiveness and patient recruitment.
Seeking to gain efficiencies, cost savings and faster enrollment timelines for vaccine clinical trials, North Carolina-based PRA Health Sciences has formed a non-exclusive strategic partnership with the Alliance for Multispecialty Research (AMR), a geographically dispersed network that represents 17 independently owned, multi-therapeutic clinical research investigative sites.
Presented at the World Vaccine Congress 2015 in Wash., D.C., the vaccine industry came to a consensus that the Alliance for Multispecialty Research had outperformed the competition in the trial network field. The Vaccine Industry Excellence (ViE) Award for Best Clinical Site/Network recognizes the efforts, accomplishments and positive contributions to the vaccine industry by a clinical research site/network.
The Alliance for Multispecialty Research (AMR), based in Spring Hill, Tenn., is offering a new gratis service developed by its Alliance of 16 independently owned and managed clinical research centers of excellence across the U.S. and implemented on several recent sponsors’ programs, including bioterrorism vaccines, obesity, and tobacco-related projects.